If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A clinical-stage drug discovery and development company based in Barcelona, Spain is offering a risk-sharing, co-development opportunity to biotechnology and/or pharmaceutical companies to find new potential medical uses for their drug of choice and/or to identify new drugs for their selected indication, using the company’s artificial intelligence platform. The company is looking for technical cooperation agreement.
A clinical-stage drug discovery and development company based in Barcelona (Spain) has developed an efficient and predictive proprietary artificial intelligence (AI) technology for drug reprofiling.
The AI platform has demonstrated success through the company’s first asset for Transthyretin Amyloidosis which reached Phase 2a completion in five years since its discovery in 2011 and was licensed for worldwide rights to a US-based pharmaceutical company. Recently, the technology has yet again proven its predictive accuracy through the Phase 2a milestone achieved by the company’s second asset for Huntington’s disease in the 3rd quarter of 2018.
The discovery and identification process is dependent on the company’s proprietary AI technology which uses a database of biological targets comprising more than 300,000 ligands and a library composed of 10,000 compounds and molecules. It includes the use of the platform’s relevant software and predictive tools needed for the course of screening.
Although the company’s business model is concentrated on the discovery and development of drugs for the CNS orphan disease space, its technology is not only limited to that therapeutic area, but is designed to perform its screenings and validations in a broad spectrum of medical indications such as in dermatology, ophthalmology, psychiatry and more.
By leveraging its proprietary AI technology, the company is offering the opportunity for a potential collaboration that follows a four-stage scope that will each yield corresponding deliverables:
1. In-silico screening – List of potential new indications/drugs to be developed (checked for patentability)
2. In-vitro validation – List of best candidate indications/drugs to be developed
3. Patent application – Patent of new use
4. In-vivo validation – Target engagement assays, Animal models
The company is seeking pharmaceutical and biotech companies for technical cooperation agreements. Depending on its strategy and preference, the partner will have freedom to decide on the scope of the collaboration by choosing up to which stage it wishes to engage in. In addition, the type of collaboration, whether a co-development where risks will be shared by both parties or a partnership where all risks will be assumed by the partner, may also be subject to the partner’s inclination.
The company’s proprietary AI technology is three times more predictive than other available technologies according to studies. In comparison, the company’s AI platform shows the following features:
- Ligand-based virtual screening equipment based on molecular fields and artificial intelligence evolutionary algorithms.
- It identifies non-structural analogs of a given compound.
- Technology based on the 3-D superposition of molecular fields.
Since its inception, the company has reached clinical phase 2a in two different programs and it is about to start its 3rd clinical trial next year. This indicates high predictive accuracy of the technology.
The most advanced asset that the technology has predicted has undergone clinical phase 2a and has already been out licensed.
The company seeks to collaborate with biotechnology and/or pharmaceutical companies that wish to expand their pipeline through finding new medical indications for their chosen drug and/or identifying new drugs that can be used for their preferred indication, and that are looking for a reliable drug discovery partner that fits strategically with their development direction.